False about Ivabradine
**Core Concept**
Ivabradine is a selective inhibitor of the I(f) channel, specifically targeting the hyperpolarization-activated cation channel (HCN4) in the sinoatrial (SA) node. This action results in a reduction of the sinoatrial node's firing rate, thereby decreasing heart rate.
**Why the Correct Answer is Right**
Ivabradine works by blocking the I(f) channel, which is responsible for the inward flow of sodium and potassium ions into the SA node. By inhibiting this channel, ivabradine decreases the slope of phase 4 depolarization, leading to a slower heart rate. This mechanism is unique among anti-arrhythmic drugs, as it does not affect the action potential duration or the refractory period.
**Why Each Wrong Option is Incorrect**
**Option A:** Ivabradine is not a beta-blocker, as it does not affect the beta-adrenergic receptors or the sympathetic nervous system.
**Option B:** Ivabradine is not primarily used for treating atrial fibrillation; it is specifically indicated for the treatment of symptomatic stable angina in patients with a left ventricular ejection fraction (LVEF) ≥35%.
**Option C:** Ivabradine does not have a significant effect on blood pressure; its primary action is on heart rate.
**Clinical Pearl / High-Yield Fact**
Ivabradine's unique mechanism of action and its effect on heart rate make it a valuable option for patients with heart failure or coronary artery disease who have a high heart rate and are not responding to beta-blockers.
**Correct Answer:** B. Ivabradine is specifically indicated for the treatment of symptomatic stable angina in patients with a left ventricular ejection fraction (LVEF) ≥35%.